Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Angela Zaccagnino"'
Autor:
Doaa Tawfik, Angela Zaccagnino, Alexander Bernt, Monika Szczepanowski, Wolfram Klapper, Albrecht Schwab, Holger Kalthoff, Anna Trauzold
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-17 (2020)
Abstract Background The human pancreatic cancer cell line A818–6 can be grown in vitro either as a highly malignant, undifferentiated monolayer (ML) or as three-dimensional (3D) single layer hollow spheres (HS) simulating a benign, highly different
Externí odkaz:
https://doaj.org/article/9b656db7e86545e5ae1471a8147f4dac
Autor:
Rosa Angela Cardone, Maria Raffaella Greco, Katrine Zeeberg, Angela Zaccagnino, Mara Saccomano, Antonia Bellizzi, Philipp Bruns, Marta Menga, Christian Pilarsky, Albrecht Schwab, Frauke Alves, Holger Kalthoff, Valeria Casavola, Stephan Joel Reshkin
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 2, Pp 155-166 (2015)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers principally because of early invasion and metastasis. The epidermal growth factor receptor (EGFR) is essential for PDAC development even in the presence of Kras, but its inhibi
Externí odkaz:
https://doaj.org/article/3cb735e04e994897beba64f72621b1dc
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 6; Pages: 5648
The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to ca
Publikováno v:
Aktuelle Urologie. 52:452-463
ZusammenfassungIn den letzten drei Jahrzehnten wurden Nierentumore, basierend auf histopathologischen und molekularen Merkmalen, immer umfassender differenziert. Dies hat inzwischen eine zunehmend größere Bedeutung für die klinische Praxis, da dif
Publikováno v:
Aktuelle Urologie. 52(5)
During the last three decades, renal tumours have become increasingly well differentiated on the basis of their histopathological and molecular features. This subtyping has increasingly impacted clinical practice because more therapeutic options are
Publikováno v:
Cancer Research. 82:5502-5502
The VEGFR/MET/AXL receptor tyrosine kinase inhibitor, Cabozantinib (Cbz), showed clinical benefits in first- and second-line treatment for selective metastatic renal cell carcinoma (mRCC) patients. We tested the molecular effects of Cbz in treatment-
Autor:
Johannes Linxweiler, Philip Zeuschner, Michael D. Menger, Matthias Saar, Dirk Himbert, Christina Körbel, Turkan Hajili, Angela Zaccagnino, Kerstin Junker, Michael Stöckle
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:The interaction between cancer cells und cancer-associated fibroblasts (CAFs) plays an important role in the biology of prostate cancer (PCa) and seems to be also mediate...
Autor:
Anna Trauzold, Angela Zaccagnino, Monika Szczepanowski, Doaa Tawfik, Albrecht Schwab, Holger Kalthoff, Wolfram Klapper, Alexander Bernt
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-17 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-17 (2020)
Background The human pancreatic cancer cell line A818–6 can be grown in vitro either as a highly malignant, undifferentiated monolayer (ML) or as three-dimensional (3D) single layer hollow spheres (HS) simulating a benign, highly differentiated, du
Autor:
Anna Trauzold, Albrecht Schwab, Ivana Novak, Christian Pilarsky, Doaa Tawfik, Susanne Sebens, Holger Kalthoff, Angela Zaccagnino
Publikováno v:
Europe PubMed Central
The altered expression and/or activity of ion channels and transporters (transportome) have been associated with malignant behavior of cancer cells and were proposed to be a hallmark of cancer. However, the impact of altered transportome in epithelia
Publikováno v:
Cancer Research. 80:5272-5272
Introduction: The tyrosine kinase inhibitors Sunitinib and Pazopanib have been established in firstline treatment of metastatic renal cell carcinoma (mRCC) patients especially in the good prognosis group. Despite the primary response many patients be